This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' CEO Chats: Regeneron and Alkermes

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) --Every night, Jim Cramer sits down with CEOs and executives on his "Mad Money" show to discuss their business, the economy, politics and more. Today we look back at his recent interviews with Leonard Schleifer, president and CEO of Regeneron (REGN - Get Report) and Richard Pops, chairman and CEO of drug maker Alkermes (AKLS), two of Cramer's favorite biotech plays.

These are excerpts from Cramer's 'Mad Money' Recap, originally published on Jan. 14, 2014.

Executive Decision: Leonard Schleifer

For his "Executive Decision" segment, Cramer spoke with Leonard Schleifer, president and CEO of Regeneron (REGN - Get Report), which today announced continued successes with its drug Eyelea, as well as a promising pipeline that includes drugs for high cholesterol, arthritis, asthma and more.

Must Read: Jim Cramer's 'Mad Money' CEO Chats: H&R Block, Finish Line

Schleifer has a lot of positive things to say about Regeneron, noting that despite analysts' calls to the contrary, Eyelea has lots of room to grow thanks to favorable demographics, new geographies and hopefully new indications for the drug later in 2014. Regeneron is also making progress on its anti-cholesterol drug, which the company hopes to file for approval early next year.

Regeneron is also developing promising treatments for the epidemic of allergic diseases that are developing, as well as treatments for genetic ailments.

When asked about the possibility of re-incorporating in Ireland, where the company already has offices, Schleifer said that Regeneron loves New York, where it's headquartered, and has no plans to leave.

Cramer said that Schleifer has made a lot of money for shareholders and he's sticking with the stock.

Executive Decision: Richard Pops

For his "Executive Decision" segment, Cramer spoke with Richard Pops, chairman and CEO of drug maker Alkermes (ALKS), another long-term Cramer fave.

Pops commented on Alkermes' recent partnership with, of all things, a mutual fund, by saying that drug companies need a strong source of capital and a strong shareholder base, and now Alkermes has a long-term strategy for both. He said his company has five or six blockbuster drugs in development and is now funded to bring them all to market.

Pops explained how its drug, ALKS 5461, is aiming to treat the five million patients a year that are not responding to traditional anti-depressant drugs. Meanwhile, ALKS 3831 hopes to offer those suffering from schizophrenia a drug that requires just six injections a year.

Alkermes is also changing the game when it comes to treating drug addiction with its drug Vivitrol. Pops said that Vivitrol has patent protection for many years to come, giving his company enough time to chip away at the conventional thinking towards drug addiction treatments and to prove the effectiveness to Vivitrol.

Cramer said he remains a believer in both Pops and Alkermes.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
REGN $379.57 5.20%
AAPL $93.17 -0.48%
FB $117.87 -0.16%
GOOG $701.67 0.86%
TSLA $214.23 -3.70%


Chart of I:DJI
DOW 17,649.58 -1.68 -0.01%
S&P 500 2,049.63 -1.49 -0.07%
NASDAQ 4,719.8330 -5.8060 -0.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs